These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 17259911

  • 21. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society.
    Menopause; 2000; 7(4):215-29. PubMed ID: 10914614
    [Abstract] [Full Text] [Related]

  • 22. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertüngealp J, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, Stevenson JC, European Menopause and Andropause Society.
    Maturitas; 2005 May 16; 51(1):8-14. PubMed ID: 15883103
    [Abstract] [Full Text] [Related]

  • 23. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
    Menopause; 2013 Sep 16; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
    [Abstract] [Full Text] [Related]

  • 24. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA.
    Climacteric; 2007 Oct 16; 10 Suppl 2():27-31. PubMed ID: 17882669
    [Abstract] [Full Text] [Related]

  • 25. The 2022 hormone therapy position statement of The North American Menopause Society.
    “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel.
    Menopause; 2022 Jul 01; 29(7):767-794. PubMed ID: 35797481
    [Abstract] [Full Text] [Related]

  • 26. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
    The NAMS 2020 GSM Position Statement Editorial Panel.
    Menopause; 2020 Sep 01; 27(9):976-992. PubMed ID: 32852449
    [Abstract] [Full Text] [Related]

  • 27. The North American Menopause Society 1998 Menopause Survey. Part I: Postmenopausal women's perceptions about menopause and midlife.
    Utian WH, Boggs PP.
    Menopause; 1999 Sep 01; 6(2):122-8. PubMed ID: 10374218
    [Abstract] [Full Text] [Related]

  • 28. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2004 Sep 01; 11(6 Pt 1):589-600. PubMed ID: 15545786
    [No Abstract] [Full Text] [Related]

  • 29. The North American Menopause Society develops consensus opinions.
    Boggs PP, Utian WH.
    Menopause; 1998 Sep 01; 5(2):67-8. PubMed ID: 9689197
    [Abstract] [Full Text] [Related]

  • 30. When is it appropriate to prescribe postmenopausal hormone therapy?
    Ettinger B, Barrett-Connor E, Hoq LA, Vader JP, Dubois RW.
    Menopause; 2006 Sep 01; 13(3):404-10. PubMed ID: 16735937
    [Abstract] [Full Text] [Related]

  • 31. Estrogen use and postmenopausal women: a basis for informed decisions. NIH Consensus Development.
    Gastel B, Cornoni-Huntley J, Brody JA.
    J Fam Pract; 1980 Nov 01; 11(6):851-60. PubMed ID: 7005387
    [Abstract] [Full Text] [Related]

  • 32. The role of calcium in peri- and postmenopausal women: consensus opinion of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2001 Nov 01; 8(2):84-95. PubMed ID: 11256879
    [Abstract] [Full Text] [Related]

  • 33. Association between premenopausal progestogen use and postmenopausal hormonal therapy in the GAZEL cohort.
    Ringa V, Fritel X, Varnoux N, Zins M, Piault S, Quelen C.
    Maturitas; 2007 Nov 20; 58(3):216-25. PubMed ID: 17919857
    [Abstract] [Full Text] [Related]

  • 34. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.
    Menopause; 2021 Sep 01; 28(9):973-997. PubMed ID: 34448749
    [Abstract] [Full Text] [Related]

  • 35. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
    Stefanick ML.
    Am J Med; 2005 Dec 19; 118 Suppl 12B():64-73. PubMed ID: 16414329
    [Abstract] [Full Text] [Related]

  • 36. Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society.
    Gambacciani M, Biglia N, Cagnacci A, Caruso S, Cicinelli E, DE Leo V, DI Carlo C, Farris M, Gambera A, Guaschino S, Lanzone A, Paoletti AM, Russo N, Vicariotto F, Villa P, Volpe A, Italian Menopause Society (SIM).
    Minerva Ginecol; 2018 Feb 19; 70(1):27-34. PubMed ID: 28975776
    [Abstract] [Full Text] [Related]

  • 37. The North American Menopause Society: from abstract to publication.
    Schnatz PF, Romegialli A, Abrantes J, Marakovits K, Cunningham D, O'Sullivan DM, North American Menopause Society.
    Menopause; 2008 Feb 19; 15(5):996-1001. PubMed ID: 18446091
    [Abstract] [Full Text] [Related]

  • 38. Postmenopausal hormone therapy and breast cancer: what is the problem?
    Kenemans P.
    Maturitas; 2005 May 16; 51(1):75-82. PubMed ID: 15883112
    [Abstract] [Full Text] [Related]

  • 39. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P, Speroff L, International Tibolone Consensus Group.
    Maturitas; 2005 May 16; 51(1):21-8. PubMed ID: 15883105
    [Abstract] [Full Text] [Related]

  • 40. Options for hormone therapy in women who have had a hysterectomy.
    Haney AF, Wild RA.
    Menopause; 2007 May 16; 14(3 Pt 2):592-7; quiz 598-9. PubMed ID: 17476150
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.